KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$9.47
+2.82% today
Updated 2026-05-06
Market cap
$557.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.64
Dividend yield
—
52W range
$2 – $14
Volume
0.9M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | $85.49M | $66.92M | $75.19M | $304.64M |
| Cash & equivalents | $76.07M | $37.73M | $34.65M | $96.62M |
| Current assets | $77.09M | $53.25M | $60.66M | $290.60M |
| Total liabilities | $131.74M | $20.25M | $26.02M | $38.06M |
| Current liabilities | $15.93M | $11.95M | $19.86M | $33.76M |
| Long-term debt | — | — | — | — |
| Shareholder equity | $-46.25M | $46.68M | $49.18M | $266.59M |
| Retained earnings | $-46.78M | $-75.68M | $-136.04M | $-263.52M |
| Accounts receivable | — | — | — | — |
| Inventory | — | — | — | — |
| Goodwill | — | — | — | — |